Diclofenac add-on to Treatment as Usual for Suicidal Patients
Primary Purpose
Depression Suicidal
Status
Withdrawn
Phase
Phase 1
Locations
Sweden
Study Type
Interventional
Intervention
sugar pill
Diclofenac
Sponsored by

About this trial
This is an interventional treatment trial for Depression Suicidal
Eligibility Criteria
Inclusion Criteria:
- Depressive disorder
- Montgomery Asberg Rating Scale Score more than 20 p.
- Recent suicide attempt (Treated as inpatient due to a recent suicide attempt)
- Informed consent
- Competence to give informed consent
Exclusion Criteria:
- Pregnancy
- Breastfeeding
- Serious somatic disease e.g. serious heart, vascular, hepatic, kidney, pulmonary, intestinal, endocrine, haematological or neurological diseases
- Ongoing substance abuse
- Schizophrenia or other psychotic disorders
- Ongoing psychosis
- Risk factors for cardiovascular events
- Ulcer or gastrointestinal bleeding
- Ongoing Electroconvulsive therapy
- Previous allergic reaction to NSAID, acetylsalicylic acid, sulfonamides or the diclofenac or sugar pill content
- Galactose intolerance, lactase deficiency or glucose-galactose malabsorption
- Ongoing treatment with warfarin or other anticoagulants
- Ongoing treatment with ACE inhibitors or angiotensin II antagonists Ongoing treatment with drugs known to effect the immune system Ongoing treatment with rifampicin, carbamazepine or barbiturates
Sites / Locations
- Psychiatry Skane
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
diclofenac
sugar pill
Arm Description
Outcomes
Primary Outcome Measures
Suicide Assessment Scale (differences in scores before and after treatment)
Secondary Outcome Measures
Montgomery Asberg Rating Scale (differences in scores before and after treatment)
Barratt Impulsiveness Scale (differences in scores before and after treatment)
Montgomery Asberg depression Ratin scale (changes in suicidality item before and after treatment)
Montgomery Asberg Rating Scale (changes in concentration item before and after treatment)
Comprehensive Psychopathological Rating Scale (changes in aggressive feelings item before and after treatment)
Comprehensive Psychopthological Rating Scale (changes in fatigue item before and after treatment)
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01413854
Brief Title
Diclofenac add-on to Treatment as Usual for Suicidal Patients
Official Title
"Antiinflammatoriska läkemedels Effekt för Att Minska Suicidalitet Hos Deprimerade Patienter Som Nyligen Har Gjort självmordsförsök"
Study Type
Interventional
2. Study Status
Record Verification Date
January 2019
Overall Recruitment Status
Withdrawn
Why Stopped
Not enough recources.
Study Start Date
August 2011 (Actual)
Primary Completion Date
August 2011 (Actual)
Study Completion Date
August 2011 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Region Skane
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to determine whether diclofenac is effective in the treatment of depressed patients with a recent suicide attempt.
Detailed Description
The study will start with a feasibility study including treatment of 10 patients with diclofenac.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Depression Suicidal
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
diclofenac
Arm Type
Active Comparator
Arm Title
sugar pill
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
sugar pill
Other Intervention Name(s)
One tablet two times daily during four weeks
Intervention Description
One tablet two times daily during four weeks
Intervention Type
Drug
Intervention Name(s)
Diclofenac
Other Intervention Name(s)
50 mg, two times daily (oral adm.) during four weeks
Intervention Description
50 mg, two times daily (oral adm.) during four weeks
Primary Outcome Measure Information:
Title
Suicide Assessment Scale (differences in scores before and after treatment)
Time Frame
four weeks of treatment
Secondary Outcome Measure Information:
Title
Montgomery Asberg Rating Scale (differences in scores before and after treatment)
Time Frame
four weeks of treatment
Title
Barratt Impulsiveness Scale (differences in scores before and after treatment)
Time Frame
four weeks of treatment
Title
Montgomery Asberg depression Ratin scale (changes in suicidality item before and after treatment)
Time Frame
four weeks of treatment
Title
Montgomery Asberg Rating Scale (changes in concentration item before and after treatment)
Time Frame
four weeks of treatment
Title
Comprehensive Psychopathological Rating Scale (changes in aggressive feelings item before and after treatment)
Time Frame
four weeks of treatment
Title
Comprehensive Psychopthological Rating Scale (changes in fatigue item before and after treatment)
Time Frame
four weeks of treatment
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Depressive disorder
Montgomery Asberg Rating Scale Score more than 20 p.
Recent suicide attempt (Treated as inpatient due to a recent suicide attempt)
Informed consent
Competence to give informed consent
Exclusion Criteria:
Pregnancy
Breastfeeding
Serious somatic disease e.g. serious heart, vascular, hepatic, kidney, pulmonary, intestinal, endocrine, haematological or neurological diseases
Ongoing substance abuse
Schizophrenia or other psychotic disorders
Ongoing psychosis
Risk factors for cardiovascular events
Ulcer or gastrointestinal bleeding
Ongoing Electroconvulsive therapy
Previous allergic reaction to NSAID, acetylsalicylic acid, sulfonamides or the diclofenac or sugar pill content
Galactose intolerance, lactase deficiency or glucose-galactose malabsorption
Ongoing treatment with warfarin or other anticoagulants
Ongoing treatment with ACE inhibitors or angiotensin II antagonists Ongoing treatment with drugs known to effect the immune system Ongoing treatment with rifampicin, carbamazepine or barbiturates
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Åsa Westrin, MD, Phd
Organizational Affiliation
Lund University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Psychiatry Skane
City
Lund
Country
Sweden
12. IPD Sharing Statement
Learn more about this trial
Diclofenac add-on to Treatment as Usual for Suicidal Patients
We'll reach out to this number within 24 hrs